Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis
Bioorganic Chemistry · 2026-08 · 178 · 109945
DOI: 10.1016/j.bioorg.2026.109945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-08. Verfasst von Lin Yue und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of High Altitude Medicine, Center for High Altitude Medicine, Department of Emergency Medicine, Institute of Disaster Medicine and Institu…. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Receptor, Transforming Growth Factor-beta Type I, Drug Design, Protein Kinase Inhibitors. Die Arbeit nennt 43 Literaturangaben. Gefördert von: West China Hospital of Sichuan University, Science and Technology Department of Sichuan Province, Sichuan University.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a progressive and fatal lung disease characterized by excessive extracellular matrix (ECM) deposition, leading to irreversible scarring and respiratory failure. With limited treatment options, there is an urgent need for novel therapeutic strategies. Activin receptor-like kinase 5 (ALK5), a type I receptor serine/threonine kinase, serves as the principal mediator of transforming growth factor-β (TGF-β) signaling and a pivotal driver of PF pathogenesis. Given the central role of ALK5 in fibrogenesis, targeting ALK5 represents a promising therapeutic approach. Conventional ALK5 inhibitors primarily target kinase activity, whereas proteolysis-targeting chimeras (PROTACs) may offer a promising therapeutic strategy by inducing degradation of the target protein. Herein, we report the discovery of a series of novel ALK5-targeting PROTAC degraders. The lead compound, A31, induced ALK5 degradation in NIH3T3 cells and demonstrated inhibition of ALK5 downstream signaling and fibroblast activation. Furthermore, A31 exhibits favorable pharmacokinetics following intraperitoneal administration, in vivo anti-fibrotic efficacy, and no significant toxicity at efficacious doses. Collectively, our study supports the feasibility of ALK5-targeting degradation as a potential therapeutic strategy for pulmonary fibrosis and highlights the therapeutic potential of PROTAC-based strategies in fibrotic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of High Altitude Medicine, Center for High Altitude Medicine, Department of Emergency Medicine, Institute of Disaster Medicine and Institute of Emergency Medicine, State Key Laboratory of Biotherapy, West Chi…
Förderung
- West China Hospital of Sichuan University
- Science and Technology Department of Sichuan Province
- Sichuan University
- National Natural Science Foundation of China
Zitieren
APA
Yue, L., Li, Y., Gan, C., Sun, M., Deng, C., Xue, T., Xie, Y., Liu, H., Liu, Z., & Ye, T. (2026). Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis. Bioorganic Chemistry, 178, 109945. https://doi.org/10.1016/j.bioorg.2026.109945
Vancouver
Yue L, Li Y, Gan C, Sun M, Deng C, Xue T, et al. Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis. Bioorganic Chemistry. 2026;178:109945. doi:10.1016/j.bioorg.2026.109945
BibTeX
@article{Yue2026,
author = {Yue, Lin and Li, Yuting and Gan, Cailing and Sun, Meng and Deng, Conghui and Xue, Taixiong and Xie, Yuting and Liu, Hongyao and Liu, Zhihao and Ye, Tinghong},
title = {Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {178},
pages = {109945},
doi = {10.1016/j.bioorg.2026.109945}
}
EUVIMED